Amedex Biotherapeutics shareholders back share authorisation and reverse split plan

Lakewood-Amedex Biotherapeutics held its annual shareholder meeting on Sept. 22, 2026; shareholders approved raising authorized common shares to 100,000,000 from 12,500,000, authorised board-led reverse stock splits up to 1-for-20, adopted an amendment to the 2020 equity incentive plan lifting the share pool to 400,000, and ratified CBIZ CPAs as independent auditor.